Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001493152-22-011609
Filing Date
2022-04-29
Accepted
2022-04-29 16:52:46
Documents
15
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 form10-ka.htm   iXBRL 10-K/A 299957
2 ex10-56.htm EX-10.56 32387
3 ex31-1.htm EX-31.1 4478
4 ex31-2.htm EX-31.2 4526
  Complete submission text file 0001493152-22-011609.txt   790044

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE qlgn-20211231.xsd EX-101.SCH 46541
6 XBRL LABEL FILE qlgn-20211231_lab.xml EX-101.LAB 158766
7 XBRL PRESENTATION FILE qlgn-20211231_pre.xml EX-101.PRE 24004
9 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 5982
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-37428 | Film No.: 22876741
SIC: 2834 Pharmaceutical Preparations